VENPOWRII
Live / Allowed — Notice of allowance issued (as of 23 Dec 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Nov 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98842385
- Mark type
- Stylized text
- Filed
- 07 Nov 2024
- Published for opposition
- 28 Oct 2025
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; pharmaceutical anticoagulants for human use; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy preparations for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic biological preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, Princeton, NJ, US
Prosecution history
- 23 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Oct 2025 — PUBLISHED FOR OPPOSITION
- 22 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Sept 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Sept 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Sept 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 25 Aug 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 25 Aug 2025 — FINAL REFUSAL E-MAILED
- 25 Aug 2025 — FINAL REFUSAL WRITTEN
- 25 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 25 Aug 2025 — NON-FINAL ACTION E-MAILED
- 25 Aug 2025 — NON-FINAL ACTION WRITTEN
- 21 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED